Biosyntech Inc. Signs Agreement With MedQualis As BST-DermOn’TM’ And BST-InPod’TM’ Clinical Trial CRO

October 19, 2005 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

BIOSYNTECH (TSX Venture:BSY) is pleased to announce the appointment of MedQualis, a contract research organization (CRO) to support BioSyntech in their upcoming BST-DermOn(TM) and BST-InPod(TM) Canadian clinical trials.

Twitter
LinkedIn
Facebook
Email
Print

Alliances